17:40 , Oct 19, 2018 |  BC Week In Review  |  Company News

Revolution acquiring Warp Drive

Revolution Medicines Inc. (Redwood City, Calif.) is expanding its cancer pipeline with the acquisition of another Third Rock Ventures portfolio company, Warp Drive Bio Inc. (Cambridge, Mass.). The financial terms of the deal are undisclosed...
00:55 , Oct 19, 2018 |  BC Innovations  |  Translation in Brief

Sorting out exosomes

A team of Japanese researchers have identified UBL3 as a new therapeutic target for cancers and neurodegenerative diseases that spread via the exosome-based intercellular communication system. The ubiquitin system sorts proteins for cellular export via...
22:17 , Oct 16, 2018 |  BC Extra  |  Company News

Revolution acquiring fellow Third Rock company Warp Drive

Revolution Medicines Inc. (Redwood City, Calif.) is expanding its cancer pipeline with the acquisition of another Third Rock Ventures portfolio company, Warp Drive Bio Inc. (Cambridge, Mass.). The financial terms of the deal are undisclosed...
00:33 , Sep 28, 2018 |  BC Innovations  |  Targets & Mechanisms

Cell metabolism’s migration

As cancer metabolism undergoes a renaissance in the clinic, with compounds targeting growth factor and nutrient sensing pathways, basic research on metabolic processes in all cells is shining light on pathways that could yield new...
16:05 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Chronic myelogenous leukemia (CML); colorectal cancer; brain cancer; sarcoma...
03:00 , Aug 10, 2018 |  BC Innovations  |  Targets & Mechanisms

Getting to function

A new target for sarcopenia that increases muscle function directly, in addition to adding muscle mass, could help address calls from patients and regulators to make functional recovery central to drug development in the indication....
21:00 , Aug 3, 2018 |  BC Extra  |  Company News

Management tracks: Cellectis, Navitor

Zafgen Inc. (NASDAQ:ZFGN) CEO Thomas Hughes has stepped down from the metabolic disease company to become CEO at Navitor Pharmaceuticals Inc. (Cambridge, Mass.). Zafgen is seeking a successor. In June, Navitor begin Phase I testing...
15:37 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

resTORbio forging ahead with anti-infective after Phase IIb readout

Data from Part 2 of a Phase IIb trial evaluating RTB101 from resTORbio Inc. (NASDAQ:TORC) to prevent respiratory tract infections showed that all three dose regimens of the candidate missed the study's primary endpoint vs....
20:57 , Jul 25, 2018 |  BC Extra  |  Clinical News

resTORbio forging ahead with anti-infective after Phase IIb readout

Data from Part 2 of a Phase IIb trial evaluating RTB101 from resTORbio Inc. (NASDAQ:TORC) to prevent respiratory tract infections showed that all three dose regimens of the candidate missed the study's primary endpoint vs....
16:27 , Jun 12, 2018 |  BioCentury  |  Emerging Company Profile

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation. The company’s platform combines synthetic and medicinal chemistry, biochemistry, and...